LUNG

Competitive advantage analysis · healthcare

Medical Devices & Diagnostics
Overall moat score
57/100
Moderate

About

Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers … Full LUNG analysis →

Competitive advantage assessment

Key strengths

  • Elite Gross Margins Gross margin quality is top-tier vs peers (score 0.75). This signals strong consumable attach-rate economics.
  • Stable Gross Margin Profile Gross margin stability is strong (score 0.99). Low volatility confirms durable consumable pricing.

Key risks

  • Weak Capital Return Profile Capital return quality is below peers (score 0.35). Low ROIC raises questions about M&A discipline and pipeline ROI.
  • Thin Interest Coverage Interest coverage lags peers (score 0.31). Thin coverage limits M&A optionality and raises refinancing risk.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Strong
84

Where LUNG ranks in Medical Devices

ranks #54 of 160 scored companies in Medical Devices by moat score — the top 34%. The widest moat in the group is iRadimed Corporation (IRMD) at 83/100.

Moat scores for companies ranked near LUNG in Medical Devices
# Company Moat score Rating
50 AdaptHealth Corp. AHCO 59/100 Moderate
51 Sight Sciences, Inc. SGHT 59/100 Moderate
52 Treace Medical Concepts, Inc. TMCI 58/100 Moderate
53 WORK Medical Technology Group L WOK 58/100 Moderate
54 LUNG LUNG 57/100 Moderate
55 Nortech Systems Incorporated NSYS 56/100 Moderate
56 Bruker Corporation BRKR 55/100 Moderate
57 Varex Imaging Corporation VREX 55/100 Moderate
58 RxSight, Inc. RXST 55/100 Moderate

See every Medical Devices & Diagnostics company ranked by moat score →

How LUNG scores on the Medical Devices & Diagnostics defenses

Pricing Power & Consumable Moat

Score 84 · 25% of the moat score

In MedTech, pricing power is rarely about the machine — it is about what the machine consumes.

R&D Pipeline & Capital Returns

Score 48 · 20% of the moat score

Research spending is how a device company keeps its installed base current, but spending alone proves nothing.

FCF Quality & Cash Conversion

Score 54 · 20% of the moat score

MedTech companies grow by acquisition, and the resulting intangible amortisation depresses reported earnings without consuming any cash.

Commercial Execution

Score 58 · 15% of the moat score

Devices are sold into hospitals and labs through committees, tenders and long qualification cycles, which makes the sales organisation expensive and hard to replicate.

Capital Structure & Resilience

Score 26 · 12% of the moat score

Serial acquirers carry debt, and the question is whether the cash flows underneath it are dependable enough to service it through a downturn.

Growth Durability

Score 41 · 8% of the moat score

Growth durability separates an expanding installed base from a good product cycle.

How each Medical Devices & Diagnostics defense is measured, in full →

Understanding LUNG's moat

What is LUNG's moat score?

LUNG (LUNG) scores 56 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #54 of 160 scored companies in Medical Devices, the top 34%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 159 companies in Medical Devices. Its strongest defense is Pricing Power & Consumable Moat (84/100) and its weakest is Capital Structure & Resilience (26/100).

How does LUNG compare with other Medical Devices companies?

LUNG ranks #54 of 160 scored companies in Medical Devices by moat score. The widest moat in Medical Devices is iRadimed Corporation (IRMD) at 83/100. The companies ranked closest are WORK Medical Technology Group L (WOK) at 58 just above it and Nortech Systems Incorporated (NSYS) at 56 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Medical Devices & Diagnostics in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 159 companies in Medical Devices. The defenses are then weighted to produce the overall score out of 100.

Why is LUNG scored with the Medical Devices & Diagnostics template?

Medical device and diagnostics companies place an instrument once and then sell the consumables, reagents and service that instrument needs for the next decade. The economics are a razor-and-blade model wrapped in regulatory approval and clinician habit, so the MedTech template scores the durability of that installed base rather than the size of any single product launch.

Which competitive defenses are measured for LUNG?

The Medical Devices & Diagnostics template measures 6 defenses, and LUNG scores: Pricing Power & Consumable Moat (84), R&D Pipeline & Capital Returns (48), FCF Quality & Cash Conversion (54), Commercial Execution (58), Capital Structure & Resilience (26), Growth Durability (41). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000